IBBQ:NSD-Invesco Nasdaq Biotechnology ETF (USD)

ETF | Others |

Last Closing

USD 24.34

Change

+0.35 (+1.46)%

Market Cap

USD 0.04B

Volume

4.95K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-07 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
QQQM Invesco NASDAQ 100 ETF

-0.12 (-0.06%)

USD 34.39B
IBIT iShares Bitcoin Trust

+5.88 (+13.46%)

USD 29.98B
ACWI iShares MSCI ACWI ETF

+0.15 (+0.12%)

USD 19.27B
JEPQ JPMorgan Nasdaq Equity Premium..

+0.02 (+0.04%)

USD 17.71B
CGABL The Carlyle Group Inc. 4.625% ..

+0.05 (+0.25%)

USD 16.14B
NVDL GraniteShares 1.5x Long NVDA D..

-2.61 (-3.14%)

USD 5.55B
TBIL Rbb Fund Inc - Us Treasury 3 M..

N/A

USD 4.32B
USCL iShares Climate Conscious & Tr..

+0.08 (+0.11%)

USD 2.36B
TSLL Direxion Shares ETF Trust - Di..

+3.44 (+18.05%)

USD 2.26B
PABU iShares Paris-Aligned Climate ..

N/A

USD 2.10B

ETFs Containing IBBQ

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.19% 60% D- 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.19% 61% D- 56% F
Trailing 12 Months  
Capital Gain 31.14% 71% C- 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.14% 71% C- 60% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -0.07% 42% F 39% F
Dividend Return 0.22% 39% F 35% F
Total Return 0.29% 22% F 10% F
Risk Return Profile  
Volatility (Standard Deviation) 11.93% 54% F 87% B+
Risk Adjusted Return 1.86% 38% F 36% F
Market Capitalization 0.04B 55% F 25% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.